Global Obesity – Epidemiology Insights and Forecast Report (Top 32 Markets) – 2020 To 2040

Global Obesity Epidemiology Insights

Thelansis’s “Global Obesity Epidemiology Insights and Forecast Report (Top 32 Markets) – 2020 To 2040″ provides an analysis of disease burden, characterized by disease definition, kidney biopsy cases, prevalence, incidence, diagnosed cases, severity, comorbidities, and clinical manifestations. Potential patient flow dynamics in disease burden are driven by shifts in demographic indicators and their correlation with age and gender distribution over time. Changes in the reported cases and long-term survival of patients may depend on diet, lifestyle, comorbid conditions, and the availability of interventions or therapies for the 32 markets (North America, Europe, Middle East, Asia Pacific, Africa, South / Latin America).

Obesity Overview

Obesity is a complex, chronic disease characterized by excessive accumulation of body fat that impairs health and increases the risk of numerous comorbidities, including type 2 diabetes, cardiovascular disease, certain cancers, and musculoskeletal disorders. It arises from an interplay of genetic, environmental, behavioral, and metabolic factors, with energy imbalance—calories consumed exceeding calories expended—being the central driver. Diagnosis is commonly based on body mass index (BMI), with obesity defined as a BMI of 30 or higher, though waist circumference and body composition measures provide additional insight into cardiometabolic risk. Clinical manifestations extend beyond physical health, as obesity is also associated with reduced quality of life, stigma, and psychological distress. Management requires a multifaceted approach combining lifestyle modification, nutritional counseling, physical activity, behavioral therapy, pharmacotherapy, and, in severe cases, bariatric surgery. Despite advances in treatment, obesity remains a global public health challenge, underscoring the need for prevention strategies, long‑term care models, and personalized interventions.

Market Definition:

  • North America (United States, Canada)
  • Europe (Austria, Belgium, Czech Republic, Denmark, Finland, France, Germany, Greece, Italy, Netherlands, Norway, Poland, Portugal, Russia, Spain, Sweden, Switzerland, United Kingdom)
  • Middle East (Saudi Arabia, UAE, Kuwait, Turkey)
  • Asia Pacific (Australia, China, Hong Kong, India, Indonesia, Japan, Malaysia, New Zealand, Philippines, Singapore, South Korea, Taiwan, Thailand, Vietnam)
  • Africa (Egypt, Nigeria, South Africa, Morocco)
  • South / Latin America (Argentina, Brazil, Chile, Colombia, Mexico, Peru)

Deliverables format and updates*:

  • Access to an interactive epidemiology platform with downloadable Excel and PPT files.
  • Global findings
  • G8 findings
  • Regional findings
  • Country-specific findings
  • Others*: regular updates, customizations, epidemiologist support
  • *As per Thelansis’s policy, we ensure that we include all the recent updates before releasing the content. Countries, subpopulations, and years of forecast can be customized as per client requirements.

Key business questions answered:

  • 20-year historical and forecast data (2020–2040)
  • Disease definition based on globally accepted and latest criteria (e.g., ICD-10 codes)
  • Granular patient population coverage by year and geography
  • Detailed segmentation by age, gender, subpopulations, comorbidities, line of therapies, etc.
  • Patient funnels
  • Country comparisons
  • Relevant clinical variables (e.g., staging/classification/severity)
  • Insights driven by robust research and estimates:
  • Published literature (e.g., peer-reviewed journal articles, registries, national surveys)
  • Primary market research with KOLs
  • RWD analysis using claims and EHR datasets
  • Proprietary mathematical models (e.g., incidence-survival model; incidence- recurrence/progression-survival model)


Read more: Global Obesity – Epidemiology Insights and Forecast Report (Top 32 Markets) – 2020 To 2040


Comments

Post a Comment

Popular posts from this blog

Retinitis Pigmentosa (RP) – Market Access and Reimbursement Insights Report – 2025

Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Thelansis’s “Retinitis Pigmentosa (RP) Market Access and Reimbursement Insights Report – 2025″ provides comprehensive payer insights on the current and evolving market access and reimbursement environments for branded and emerging drugs in the indication. Our team understands the criticality of payer research and insights generation, as well as their importance during drug development, pre-market launch strategy, and post-marketing activities. Key business questions answered: Market access and reimbursement for current therapies Coverage on plans Market access restrictions Rebates and contracting Factors influencing formulary access HEOR requirements and influence, etc. Expected market access and reimbursement for key emerging therapies Level of awareness Anticipated coverage on plans Factors that would improve mar...
Read more

Uncomplicated Gonorrhea – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2024 To 2034

  Uncomplicated Gonorrhea Market Outlook Thelansis’s “Uncomplicated Gonorrhea Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Uncomplicated Gonorrhea treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China). Uncomplicated Gonorrhea Overview Uncomplicated gonorrhea is a common sexually transmitted infection (STI) caused by Neisseria gonorrhoeae, a bacterium that primarily affects the mucous membranes of the genital, rectal, and throat areas. The infection spreads through unprotected sexual contact and often presents mild or no symptoms, making early detection challenging. When symptoms do appear, they generally include a burning sensation...
Read more

Chondrosarcoma – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Image
  Chondrosarcoma is a rare malignant tumor that forms a cartilaginous matrix. Chondrosarcomas arising de novo are termed primary chondrosarcomas, while those developing in pre-existing benign cartilaginous tumors such as osteochondroma or enchondroma are referred to as secondary chondrosarcomas. CHS constitutes various groups of malignant bone tumors and encompasses multiple histological subtypes. Overall, conventional CHS is the most common subtype. It accounts for 85% of CHS, followed by dedifferentiated (10%), mesenchymal and clear cell CHS, these two representing less than 2% of all CHS cases. Conventional CHS can develop de novo or in a pre-existing enchondroma and osteochondroma. CHS is classified into three grades based on cellular atypia, mitotic figures, and cellularity. CHS grades 1 and 2 are represented by 85% of all CHSs, 15% of cases are grade 3, and the dedifferentiated CHS. According to the latest WHO recommendations, CHS should be classified into central or secondar...
Read more